Clinical Research Directory
Browse clinical research sites, groups, and studies.
Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana
Summary
Thyroid eye disease frequently causes upper eyelid retraction, which can lead to ocular surface complications and cosmetic concerns. Several medical and surgical treatments have been proposed; however, minimally invasive therapies remain of interest. This study evaluates the efficacy of local triamcinolone acetonide injection administered through transconjunctival and transseptal routes for the treatment of upper eyelid retraction in patients with inactive thyroid eye disease. Patients with thyroid eye disease and upper eyelid retraction were treated with a combined subconjunctival and transcutaneous injection of triamcinolone acetonide. Clinical measurements including margin reflex distance 1 (MRD1), palpebral fissure height, visual acuity, intraocular pressure, and Clinical Activity Score (CAS) were evaluated before treatment and one month after intervention.
Official title: Efficacy of Transseptal and Transconjunctival Triamcinolone Acetonide Injection for the Treatment of Upper Eyelid Retraction in Patients With Thyroid Eye Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2024-06-20
Completion Date
2025-02-20
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
Triamcinolone Acetonide
Triamcinolone acetonide administered as a subconjunctival injection (0.3 mL; 12 mg) above the superior tarsal border combined with a transseptal upper eyelid injection (0.2 mL; 8 mg).
Locations (1)
Instituto de Oftalmologia F.A.P. Conde de Valenciana, I.A. P.
Mexico City, Mexico